ARTICLE | Clinical News
Ibrance palbociclib regulatory update
September 26, 2016 7:00 AM UTC
EMA’s CHMP recommended approval of Ibrance palbociclib from Pfizer to treat hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in combination with Faslodex fulvest...